Biochemical Recurrence Rate of Radical Prostatectomy Combined With Neoadjuvant and Adjuvant Chemotherapy in High Risk Prostate Cancer

Not Applicable

• Conditions: Prostate Cancer
• Interventions: Drug: DOCETAXEL

• Registration Number: NCT01530295
• Lead Sponsor: Hanjong Ahn

Brief Summary

Effect of Radical Prostatectomy Combined with Neoadjuvant and Adjuvant Chemotherapy in Patients with High Risk Prostate Cancer.

The purpose of this study is to evaluate whether neoajuvant and adjuvant docetaxel and prednisone are effective in the treatment of high risk localized prostate cancer.

Detailed Description

The purpose of this study is to evaluate whether neoajuvant and adjuvant docetaxel and prednisone are effective in the treatment of high risk localized prostate cancer.

Study Timeline

• Study Start: 2008-07
• Study First Submitted: 2011-06-22
• Status Verified: 2012-02
• Study First Submitted QC: 2012-02-07
• Last Update Submitted: 2012-02-07
• Study First Posted: 2012-02-09
• Last Update Posted: 2012-02-09
• Primary Completion: 2012-07
• Study Completion: 2012-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Male
• Target Recruitment: 70

Inclusion Criteria

• Prostate Cancer
• PSA > 20 OR
• Clinical Stage > T2C OR
• GS > 7

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
contol	DOCETAXEL	control group
chemotherapy	DOCETAXEL	neoadjuvant chemotherapy

Primary Outcome Measures

Name	Time	Method
biochemical recurrence rate of Radical Prostatectomy Combined with Neoadjuvant and Adjuvant Chemotherapy in Patients with High Risk Prostate Cancer	2 Years After RRP

Trial Locations

Locations (1)

Jungmin Lee; 🇰🇷 Seoul, Korea, Republic of